ValenzaBio Overview
- Year Founded
-
2019
- Status
-
Acquired/Merged
- Employees
-
10
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$130M
ValenzaBio General Information
Description
Developer of an antibody therapy designed to provide safe and effective treatment options for patients with unmet needs. The company's therapies include several monoclonal antibodies targeting surface antigens to reduce pathogenic subpopulations of autoreactive cells, enabling researchers to devise new treatment options for patients with autoimmune and inflammatory diseases.
Contact Information
Website
valenzabiotech.comCorporate Office
- 6701 Democracy Boulevard
- Suite 300
- Bethesda, MD 20817
- United States
Corporate Office
- 6701 Democracy Boulevard
- Suite 300
- Bethesda, MD 20817
- United States
ValenzaBio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 04-Jan-2023 | $130M | Completed | Generating Revenue | ||
| 2. Early Stage VC (Series A) | 09-Apr-2021 | Completed | Pre-Clinical Trials | |||
| 1. Seed Round | 27-Feb-2020 | $14.5M | $14.5M | Completed | Pre-Clinical Trials |
ValenzaBio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Seed |
ValenzaBio Comparisons
Industry
Financing
Details
ValenzaBio Competitors (41)
One of ValenzaBio’s 41 competitors is Pharmacyclics, a Venture Capital-Backed company based in San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Pharmacyclics | Venture Capital-Backed | San Francisco, CA | ||||
| Centrose | Venture Capital-Backed | Madison, WI | ||||
| Confo Therapeutics | Venture Capital-Backed | Ghent, Belgium | ||||
| Vera Therapeutics | Formerly VC-backed | Brisbane, CA | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA |
ValenzaBio Signals
ValenzaBio Former Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Fidelity Management & Research Company | Asset Manager | Minority | ||
| Ikarian Capital | Hedge Fund | Minority | ||
| Janus Henderson Investors | Asset Manager | Minority | ||
| Opaleye | Hedge Fund | Minority | ||
| Pierre Fabre | Holding Company | Minority |
ValenzaBio FAQs
-
When was ValenzaBio founded?
ValenzaBio was founded in 2019.
-
Where is ValenzaBio headquartered?
ValenzaBio is headquartered in Bethesda, MD.
-
What is the size of ValenzaBio?
ValenzaBio has 10 total employees.
-
What industry is ValenzaBio in?
ValenzaBio’s primary industry is Biotechnology.
-
Is ValenzaBio a private or public company?
ValenzaBio is a Private company.
-
What is the current valuation of ValenzaBio?
The current valuation of ValenzaBio is .
-
What is ValenzaBio’s current revenue?
The current revenue for ValenzaBio is .
-
How much funding has ValenzaBio raised over time?
ValenzaBio has raised $93.9M.
-
Who are ValenzaBio’s investors?
Fidelity Management & Research Company, Ikarian Capital, Janus Henderson Investors, Opaleye, and Pierre Fabre are 5 of 6 investors who have invested in ValenzaBio.
-
Who are ValenzaBio’s competitors?
Pharmacyclics, Centrose, Confo Therapeutics, Vera Therapeutics, and Inovio Pharmaceuticals are some of the 41 competitors of ValenzaBio.
-
When was ValenzaBio acquired?
ValenzaBio was acquired on 04-Jan-2023.
-
Who acquired ValenzaBio?
ValenzaBio was acquired by Acelyrin.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process